Oral Bisoprolol for the treatment of non-resolving central serous chorioretinopathy: A case report
<p>Purpose: To evaluate the effect of the beta blocker Bisoprolol in the treatment of chronic central serous chorioretinopathy (CSC).</p><br><p>Methods: Five patients with non-resolving CSC were treated with oral Bisoprolol 2,5 mg once a day for three months. The best-correct...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Journal of Clinical Research and Ophthalmology - Peertechz Publications,
2020-06-12.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <p>Purpose: To evaluate the effect of the beta blocker Bisoprolol in the treatment of chronic central serous chorioretinopathy (CSC).</p><br><p>Methods: Five patients with non-resolving CSC were treated with oral Bisoprolol 2,5 mg once a day for three months. The best-corrected visual acuity (BCVA), central macular thickness (CMT) and sub-retinal fluid (SRF) horizontal diameter recorded at baseline and at 1, 2, and 3 months by optical coherence tomography (OCT) were analyzed.</p><br><p>Results: All the patients achieved a full visual recovery after 3 months of treatment and there was no evidence of SRF at the last OCT follow-up. No side effect was recorded.</p><br><p>Conclusions: These results suggest that oral Bisoprolol may be effective in the treatment of chronic CSC and could be considered as a potential therapy choice in those cases at risk of diffuse retina pigment epitheliopathy.</p> |
|---|---|
| DOI: | 10.17352/2455-1414.000070 |